Facebook Twitter The New York Department of Health published an announcement this week that was passed on to health care providers and health care facilities regarding two new COVID-19 oral therapies, Paxlovid from Pfizer, and molnupiravir from Merck, that states they will prioritize access to this drug based on race.

Eve Herold is a science writer specializing in issues at the intersection of science and society. She has written and spoken extensively about stem cell research and regenerative medicine and the social and bioethical aspects of leading-edge medicine. Her 2007 book, Stem Cell Wars, was awarded a Commendation in Popular Medicine by the British Medical Association.